AzTrials
AzTrials

Inguinal HerniaNCT06789185

Effects of Esketamine at Subanesthetic Dose on Emergence Delirium in Preschool Children Undergoing Ambulatory Laparoscopic Surgery

A study testing 0.1mg/kg esketamine, 0.2mg/kg esketamine and 0.1ml/kg normal saline in people with Inguinal Hernia, run by Qiu jinpeng at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Emergence delirium (ED) is a manifestation of acute postoperative brain dysfunction that occurs with a relatively high frequency after pediatric anesthesia. The incidence varies depending on the diagnostic criteria used and the combination of administered anesthetic drugs. Read more about this study

Who is it for?
Ages 24 to 71 months
Conditions the study is for
Inguinal Hernia
What is being tested?
0.1mg/kg esketamine, 0.2mg/kg esketamine and 0.1ml/kg normal saline
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
96 participants
Where
1 siteChina
Study dates
7 Feb 2025to 16 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 24 to 71 months
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • laparoscopic inguinal hernia repair under general anesthesia
  • aged 24~71 months
  • American Society of Anesthesiologists Physical Status I or II
  • body mass index for age between the 5th and 85th percentiles

Who cannot join

  • allergy to esketamine
  • abnormal liver or kidney function
  • glaucoma or neurological disorders
  • cardiovascular or endocrine dysfunction
  • asthma or respiratory infection in the last 2 weeks
  • developmental delay

Trial locations and contacts

1 site in 1 country.

China1 site
  • The Children's Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310052

Other trials in China

About this study

Emergence delirium (ED) is a manifestation of acute postoperative brain dysfunction that occurs with a relatively high frequency after pediatric anesthesia. The incidence varies depending on the diagnostic criteria used and the combination of administered anesthetic drugs. The goal of this clinical trial is to investigate whether a subanesthetic dose of esketamine can reduce incidence of ED.

Conditions
Inguinal Hernia
Being tested
0.1mg/kg esketamine, 0.2mg/kg esketamine, 0.1ml/kg normal saline
Medical subject headings
Hernia, Inguinal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • 0.1mg/kg esketamineDrug

    Intravenous injection 0.1mg/kg esketamine about 5min before the end of the surgery

  • 0.2mg/kg esketamineDrug

    Intravenous injection 0.2mg/kg esketamine about 5min before the end of the surgery

  • 0.1ml/kg normal salineDrug

    Intravenous injection 0.1ml/kg normal saline about 5min before the end of the surgery

Study groups in NCT06789185
Study groupRoleWhat they receive
group S1 (0.1mg/kg esketamine)ExperimentalNot described
Receives: Drug: 0.1mg/kg esketamine
group S2 (0.2mg/kg esketamine)ExperimentalNot described
Receives: Drug: 0.2mg/kg esketamine
group C (0.1ml/kg Normal saline)Placebo comparatorNot described
Receives: Drug: 0.1ml/kg normal saline

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. The incidence of emergence delirium

    The pediatric anesthesia emergence delirium scale consists of four items. Each item is scored 0-4 yielding a total between 0 and 20. The degree of emergence delirium increased directly with the total score. Pediatric anesthesia emergence delirium scores ≥10 at any time indicates presence of emergence delirium.

    Measured: Within up to 30 minutes after emergence from anesthesia

Secondary outcomes (7)
  1. Tracheal catheter extubation time

    The time from the cessation of sevoflurane to the point when the tracheal catheter would be remove.

    Measured: Within up to 30 minutes after operation

  2. emergence from anesthesia time

    The time from the cessation of sevoflurane to the point when the child would respond to sound stimuli or open their eyes.

    Measured: Within up to 30 minutes after operation

  3. The incidence of postoperative pain

    The FLACC scale consists of five items. Each item is scored 0-2 yielding a total between 0 and 10. The degree of pain increased directly with the total score. FLACC scores 4 or greater indicates presence of emergence delirium.

    Measured: Within up to 30 minutes after operation

  4. Recovery time

    The time from the cessation of sevoflurane to the point when the child was awakened and responded readily to their name spoken in a normal tone of voice.

    Measured: Within up to 50 minutes after operation

  5. The incidence of adverse effects

    Postoperative nausea, vomiting, salivation, bradycardia, hypotension, and respiratory depression within 24 hours after surgery.

    Measured: 24 hours after surgery.

  6. Blood pressure

    Blood pressure of children were measured at 0min, 5min, 10min and 20min after injection of study drug or normal saline.

    Measured: Intraoperative and up to postoperative 20 minutes

  7. heart rate

    heart rate of children were measured at 0min, 5min, 10min and 20min after injection of study drug or normal saline.

    Measured: Intraoperative and up to postoperative 20 minutes

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Jan 2025
  2. Study start7 Feb 2025
  3. Primary completion16 May 2025
  4. Study completion16 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
96 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06789185
Sponsor's protocol ID
2024-IRB-0377-P-01
Status last verified
May 2025
First submitted
17 Jan 2025
Last updated
22 May 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing 0.1mg/kg esketamine, 0.2mg/kg esketamine and 0.1ml/kg normal saline in people with Inguinal Hernia, run by Qiu jinpeng at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 22 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

The incidence of emergence delirium (time frame: Within up to 30 minutes after emergence from anesthesia). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 May 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in